nach oben

Clinical and Translational Oncology

Erschienen in:

01.09.2012 | Research Article

Chemotherapy at the end of life: up until when?

verfasst von: Jaime Sanz Ortiz

Erschienen in: Clinical and Translational Oncology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Aim

The aim of this study is to analyze the use of CT in terminal stage cancer and the percentage of patients who received UCPD in 2009 and 2010 on the Medical Oncology and Palliative Home Care integrated service (UCPD) ward of the Marqués de Valdecilla University Hospital.

Method

Retrospective analysis of death rate registered on the Medical Oncology ward for 2009 and 2010 and the recorded date of the last CT given. The data are analyzed using the SPSS version 15.0 statistic package. Data were obtained from the Database Minimum Set for oncology admissions.

Results

The death rate on the Medical Oncology ward is 22–24 %. Total number of cases studied is 303. 47 % of patients are aged 60 or younger. 81.8 % (248) received active cancer treatment; of these, 138 (55.6 %) in the last month, and 84 (33.8 %) in the last 2 weeks. Only 66 patients out of those who died on the ward (21 %) were previously sent to the UCPD.

Conclusions

Even when it is known that the majority of cancer patients become resistant to CT at the end of their lives, it is often given to patients of all ages. The request for palliative care is rare and often late.

Lorenz KA, Lynn J, Dy SM, Shugarman LR, Wilkinson A, Mularski RA et al (2008) Evidence for improving palliative care at the end of the life: a systematic review. Ann Intern Med 148:147–159PubMed

Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 20.00: cancer incidence, mortality and prevalence word wide. Version 1.0. IARC CancerBase N. 5.Lyon IARC Press

Natale RB, Zaretsky SusanL (2002) ZD1839 (Iressa™): what’s in it for the patient? Oncologist 7(suppl 4):25–30PubMedCrossRef

García Jordá E (2010) Cancer in Spain. Clin Transl Oncol 12:158–159PubMedCrossRef

Sanz-Ortiz J (2002) Oncología Médica y Cuidados Paliativos. Estudio de campo. VIII Congreso Nacional de Oncología Médica, 6–9 Octubre Hotel Meliá Valencia 2002. Libro de Ponencias: p 121; Sociedad Española de Oncología Médica (SEOM)

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistic 2006. CA Cancer J Clin 56:106–130PubMedCrossRef

Sanz-Ortiz J, Mayorga M, Martín Carnicero A (2010) La autopsia clínica en oncología: ¿está en crisis? Med Clin (Barc). doi:10.1016/j.medcli.2009.11.019

Sanz Ortiz J (2003) Nuevas dianas moleculares en la terapia del cáncer ¿Tienen función paliativa? Med Pal (Madrid) 10(4):220–225

Murillo RJ, Koeller J (2006) Chemotherapy given near the end or life by community oncologist for advanced non-small cell lung cancer. Oncologist 11:1095–1099PubMedCrossRef

10.

Raby B, Pater J, Mackillop W (1995) Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol 13:1904–1911PubMed

11.

Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with non-small cell lung cancer: descriptive study based scripted interviews. BMJ 317:771–775PubMedCrossRef

12.

Kean B, Oh D-Y, Lee S, Kim D-W, Kim MR, Im S-A et al (2008) Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol 38(5):381–386. doi:10.1093/jjco/hym031 CrossRef

13.

Earle CC, Landrum MB, Souza JM, Neville V, Weeks JC, Ayanian JZ et al (2008) Aggressiveness of cancer near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866PubMedCrossRef

14.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Vicki AJ, Constance MD, Craig DB, Juliet J, William FP, Andrew B, Thomas JL (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742PubMedCrossRef

15.

Fundación ECO (Fundación para la Excelencia y la Calidad de la Oncología). Alerta de la incidencia de cáncer en menores de 65 años. Valencia 3 Febrero 2011. http://www.fundacioneco.es/images/stories/ECO/Comunicacion/NoticiasInteres/NdPFundacionECO %20Dia %20Mundial %20Contra %20el %20Cancer %202011.pdf

16.

GLOBOCAN 2008. http://globocan.iarc.fr/factsheets/cancers/all.asp (último acceso Marzo 2011)

17.

Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Arlene SA (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643PubMed

18.

Yun YH, Miyoung K, Sang Min P, Samyong K, Jong Soo C, Ho-Yeong L, Chang Geol L, Youn Seon C, Youn Seon H, Si-Young K, Dae Seog H (2007) Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 72:164–171PubMedCrossRef

19.

Hashimoto K, Yonemori K, Katsumata N, Hotchi M, Kouno T, Shimizu C, Tamura K, Ando M, Takeuchi M, Fujiwara Y (2009) Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist 14:752–759. http://www.TheOncologist.com

20.

Sahm S, Will R, Hommel G (2005) What are cancer patients’ preferences about treatment at the end of life, and who should start talking about it? A comparison with healthy people and medical staff. Support Care Cancer 13:206–214PubMedCrossRef

21.

Sánchez- Muñoz A, Pérez-Ruiz E, Sáez MI, Trigo JM, Galindo MM, Manzaneque L, Jiménez B, Muros B, Alba E (2011) Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clin Transl Oncol 13(6):426–429PubMedCrossRef

22.

Romaní Costa V, López E, Rodríguez Carballeira M, Almagro Mena P (2010) Morir en un hospital de agudos. Análisis de la situación de últimos días. Med Pal (Madrid) 17(4):222–225

23.

NCCN Clinical Practice Guidelines in Oncology (2008) Palliative care V.1.2008. Standards of Palliative Care (Pal-1)

24.

Huskamp HA, Keating NL, Malin JL, Zaslavsky AM, Weeks JC, Earle CC, Teno JM, Virnig BA, Kahn KL, He Y, Ayanian JZ (2009) Discussion with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med 169:954–962PubMedCrossRef

25.

Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in aggressiveness of cancer care the end of life. J Clin Oncol 22:315–321PubMedCrossRef

26.

Malin JL (2004) Bridging the divide: integrating cancer-directed therapy and palliative care. J Clin Oncol 22:3438–3440PubMedCrossRef

27.

National Consensus Project for Quality Palliative Care (2004) Clinical Practice Guidelines for quality palliative care. http://www.nationalconsensusproject.org

28.

Cherny NI, Portenoy NK (1994) Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 10(2):31–38PubMed

29.

Porta-Sales J, Núñez Olarte JM, Altisent Trota R, Bisbert Aguilar A, Loncan Vidal P, Muñoz Sánchez D et al (2002) Aspectos éticos de la sedación en cuidados paliativos. Med Pal (Madrid) 9(1):41–46

30.

Doyle D (1992) Have we looked beyond the physical and psychosocial? J Pain Symptom Manag 7(5):302–311CrossRef

31.

Sanz Ortiz J, Martín Carnicero A (2009) Desasosiego o “disconfortabilidad”: ¿un síntoma refractario en la fase final de la vida? Med Clin (Barc) 132(17):669–670CrossRef

32.

Porta Sales J, Ylla-Catalá Boré A, Estibalez Gil I, Griman Malet A, Lafuerza Torres M, Nabal Vicuña C et al (1994) Estudio multicéntrico catalana-balear sobre la sedación Terminal en Cuidados Paliativos. Med Pal (Madrid) 6(4):153–158

33.

Sulmasy DP, Pellegrino ED (1999) The rule of double effect: clearing up the double talk. Arch Intern Med 159:545–550PubMedCrossRef

34.

Quill TE, Dresser R, Brock DW (1997) The rule of double effect a critique of its role in end-of-life decision making. N Engl J Med 337:1768–1771PubMedCrossRef

35.

Sanz Ortiz J (2008) La sedación paliativa como lex artis en el cuidado del final de la vida. PSICOONCOLOGÍA 5(2–3):265–277

36.

Alvarado-Cabrero I (2007) La autopsia: ¿ha muerto? Rev Med Mex Seguro Soc 45(1):1–2

37.

Burton JL, Underwood J (2007) Clinical, educational, and epidemiological value of autopsy. Lancet 369(9571):1471–1480PubMedCrossRef

38.

Petri CAN (1993) Decrease in the frequency of autopsies in Denmark after the introduction of a new Autopsy Act. Int J Qual Health Care 5:315–318CrossRef

39.

Horowitz RE, Naritoku WY (2007) The autopsy as a performance measure and teaching tool. Human Pathol 38:688–695CrossRef

40.

Skrabanek P (ed) (1999) La ideología de la salud. En: La muerte de la medicina con rostro humano. Diaz Santos S. A. Madrid, pp 1–35

41.

Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA (2009) Effects of palliative care intervention on clinical outcomes in patients with advanced cancer. The project ENEABLE II Randomized Controlled Trial. JAMA 302(7):741–749PubMedCrossRef

42.

Thomas JS, Bruce EH (2011) Bending the cost in cancer care. N Engl J Med 364(21):2060–2065CrossRef

43.

Gómez- Batiste X, Tuca A, Porta-Sales J, Amor M, Espinosa J, Borrás JM, De la Mata I, Castellsagué J (2006) Resource consumption and cost of palliative care servicies in Spain: a multicenter prospective study. J Pain Symptom Manage 31(6):522–532PubMedCrossRef

44.

Hui D, Elsayem A, De la Cruz M et al (2010) Availability an integration of palliative care at USS cancer centers. JAMA 303:1054–1061PubMedCrossRef

45.

Dalal Sh, Palla Sh, Hui D, Li N, Chacko R, Li Zh, Fadul N, Scott Ch, Thorton V, Colman B, Amin Y, Bruera E et al (2011) Association between a name change from palliative to supportive care and the timing of patient referrals at a Comprehensive Cancer Center. Oncologist 16:105–111PubMedCrossRef

46.

Sanz Ortiz J (2011) Quimioterapia en la fase final de la vida: ¿es compasiva? Med Clin (Barc) 136(8):343–344CrossRef

47.

(1998) Cancer care during the last phase of life. ASCO SPECIAL ARTICLE. J Clin Oncol 16:1986–1996

Titel: Chemotherapy at the end of life: up until when?
verfasst von: Jaime Sanz Ortiz
Publikationsdatum: 01.09.2012
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 9/2012
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0847-6

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Chemotherapy at the end of life: up until when?

Abstract

Aim

Method

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Aim

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2012

Comments to SEOM clinical guidelines for the treatment of thyroid cancer

Promises and pitfalls of new technology in radiotherapy

Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

Trends in the lung cancer incidence and mortality in the Slovak and Czech Republics in the contexts of an international comparison

The association of annexin A2 and cancers

Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie